Skip to main
BCAX

BCAX Stock Forecast & Price Target

BCAX Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 29%
Buy 43%
Hold 29%
Sell 0%
Strong Sell 0%

Bulls say

Bicara Therapeutics Inc. is positioned positively within the clinical-stage biopharmaceutical landscape due to the efficacy of its proprietary ficerafusp alfa therapy, which showcases a meaningful improvement in objective response rates when compared to existing treatments like Keytruda. Specifically, ficerafusp alfa, in combination with Keytruda, demonstrated a median progression-free survival (mPFS) of 9.9 months and a median overall survival (mOS) of 21.3 months, notably exceeding prevailing metrics in similar patient populations. This compelling data suggests that Bicara's innovative bifunctional antibody approach could offer significant advantages over current therapies, underscoring a bullish outlook for the company's stock.

Bears say

Bicara Therapeutics Inc reported a net loss of $0.50 per share for the second quarter of 2025, consistent with prior estimates, indicating ongoing financial challenges. The company's outlook is further complicated by substantial risks, including the potential for negative clinical results with its lead therapy ficerafusp alfa, delays in progressing to registrational trials, and competitive pressures from other bispecific therapies in development. Additionally, there is a significant risk of long-term dilution which could inhibit shareholder value, reinforcing concerns about the company's financial viability moving forward.

BCAX has been analyzed by 7 analysts, with a consensus rating of Buy. 29% of analysts recommend a Strong Buy, 43% recommend Buy, 29% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Bicara Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Bicara Therapeutics Inc (BCAX) Forecast

Analysts have given BCAX a Buy based on their latest research and market trends.

According to 7 analysts, BCAX has a Buy consensus rating as of Jan 10, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $25.29, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $25.29, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Bicara Therapeutics Inc (BCAX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.